Scandion Oncology

Scandion Oncology aimed to address the critical unmet need of cancer drug resistance by developing adjunctive, biomodulating therapies. Its lead asset, SCO-101, advanced to Phase 2 trials in metastatic colorectal cancer (mCRC) and Phase 1b in pancreatic cancer, targeting the ABCG2 efflux pump and UGT1A1 enzyme. Despite achieving clinical milestones, the company's strategic path to partnership or further funding was not realized, leading to a shareholder decision to liquidate the company in early 2025 and distribute remaining assets.

A first-in-class biomodulation platform using small molecules to inhibit the ABCG2 drug efflux pump and modulate the UGT1A1 metabolic enzyme, aiming to reverse resistance to standard chemotherapies.

Competition included historical efforts against other efflux pumps, broad-spectrum chemosensitizers, and the dominant industry strategy of developing next-generation targeted therapies. Scandion's first-in-class, dual-mechanism approach was its key differentiator but remained unproven.